Main Text {#S1}
=========

*Gli2^tg^* mice, in which the bovine *K5* promoter drives the constitutive expression of mouse Gli2[@R6], develop BCC and BFH[@R6],[@R7], which are both linked to deregulated Hh signaling in humans[@R7],[@R8]. *Gli2^tg^* mice show a reproducible pattern of lesions on the ear that successively involves hyper-keratosis (flaking), thickening and hyperpigmentation ([Supplemental Fig. 1a](#SD1){ref-type="supplementary-material"}). Mice were scored as positive for the onset of lesions upon the first sign of macroscopic hyperkeratosis in ear tissue. Histologically, the lesions present between P80 and P120 resemble BFH as described [@R7],[@R8]. By P180, larger, nodular, BCC-like tumors frequently occur deeper in the dermis ([Supplemental Fig. 1a](#SD1){ref-type="supplementary-material"}). Male *Gli2^tg^* mice consistently develop lesions earlier than females ([Supplemental Fig. 1b](#SD1){ref-type="supplementary-material"}). Induction of *K17*, a Gli target gene[@R9], is the main alteration in keratin expression prior to onset of lesions in *Gli2^tg^* epidermis ([Supplemental Fig. 1c](#SD1){ref-type="supplementary-material"}).

*Gli2^tg^* and *K17^−/−^* mice[@R6],[@R10] were interbred so as to assess the impact of *K17* loss on genesis of BFH-like tumors. Appearance and progression of hamartoma-like lesions were captured from P30 to P125. At P80, epithelial lesions are clearly less pronounced in *Gli2^tg^/K17^−/−^* than in *Gli2^tg^* ear tissue ([Fig. 1a](#F1){ref-type="fig"}; male data shown). In male *Gli2^tg^* and *Gli2^tg^/K17^−/−^* mice the average onset of lesions is 65±2 days (n=32) and 91±2 days (n=31; p\< 0.01), respectively. In females, onset is at 80±5 days (Gli2^tg^; n=22) vs. 101±2 days (Gli2^tg^/K17^−/−^; n=21; p\< 0.01)([Fig. 1b](#F1){ref-type="fig"}; [Supplemental Fig. 2a](#SD1){ref-type="supplementary-material"}). *Gli2^tg^* mice lacking K14[@R11] do not display such a delay ([Fig. 1c](#F1){ref-type="fig"}), establishing specificity. Gli2 transgene expression is similar in both genotypes ([Fig. 1d](#F1){ref-type="fig"}). Loss of *K17* does not impact Gli2 subcellular localization or hedgehog signaling ([Supplemental Fig. 2, b--d](#SD1){ref-type="supplementary-material"}). Therefore, the absence of K17 causes a delay in the inception of BFH-like skin tumors in *Gli2^tg^* mice.

Histological anomalies common to Hh pathway-activated mouse skin[@R7] were scored in *Gli2^tg^* and *Gli2^tg^/K17^−/−^* ear tissue ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Such anomalies, absent in wildtype and *K17^−/−^* mouse ears ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}), are prominent in *Gli2^tg^* ear but markedly reduced in *Gli2^tg^/K17^−/−^* ear ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Overall tissue thickness and penetration of epithelial downgrowths are also reduced in *Gli2^tg^/K17^−/−^* ear tissue ([Supplementary Fig. 3d,e](#SD1){ref-type="supplementary-material"}). K17, K5, and K14 are uniformly distributed in the lesional epithelium ([Supplemental Fig. 3f](#SD1){ref-type="supplementary-material"}). Co-assembly of K5 and K17 in *Gli2^tg^* lesional epithelium is conveyed by their co-localization and co-immunoprecipitation ([Supplemental Fig. 3g,h](#SD1){ref-type="supplementary-material"}). The wound-inducible K6α, K6β and K16, absent in intact epidermis, are induced in the upper layers of thickened *Gli2^tg^* epidermis, preferentially, but are markedly reduced in *Gli2^tg^/K17^−/−^* skin ([Supplemental Fig. 3f,i](#SD1){ref-type="supplementary-material"}).

Reduced proliferation, rather than increased cell death, is a key contributor to delayed tumor onset in *Gli2^tg^/K17^−/−^* skin. Relative to *Gli2^tg^*, indeed, the frequency of mitotically-active cells is depressed by \> 3-fold in *Gli2^tg^/K17^−/−^* ear epithelium ([Fig. 1e--g](#F1){ref-type="fig"}). In contrast, TUNEL-positive, apoptotic cells are restricted to the upper epidermis of lesional skin and show similar density in both genotypes ([Fig. 1h](#F1){ref-type="fig"}).

Inflammation has emerged as a driver of angiogenesis and tumor growth[@R12] and coincides with K17 induction and loss of barrier function in several skin diseases[@R13],[@R14]. Immunoreactivity for markers of innate immune cells (CD11b), T cells (Thy-1), and phagocytes (iNOS) are enhanced in *Gli2^tg^* compared to *Gli2^tg^/K17^−/−^* ear skin of p80 male mice ([Fig. 2a](#F2){ref-type="fig"}). PECAM staining is also decreased in *Gli2^tg^/K17^−/−^* ear skin ([Fig. 2a](#F2){ref-type="fig"}), reflecting decreased angiogenesis. Myeloperoxidase (MPO) enzymatic activity, inherent to neutrophils[@R15], is increased 17.4 ± 0.5 fold in P80 male *Gli2^tg^* ear tissue but only 5.8 ± 0.1 fold in *Gli2^tg^/K17^−/−^* males (data normalized to P80 female *Gli2^tg^* ear; [Fig. 2b](#F2){ref-type="fig"}). Female *Gli2^tg^/K17^−/−^* mice also show a reduced level of MPO activity at P80, being at 0.75 fold of that seen in *Gli2^tg^* controls ([Fig. 2b](#F2){ref-type="fig"}). Skin barrier integrity, assessed via a whole-mount dye penetration assay[@R16], is intact as expected in P70 wildtype ear skin ([Fig. 2c](#F2){ref-type="fig"}). In contrast, a sizable portion of the ear is dye-permeable in P70 *Gli2^tg^* mice ([Fig. 2c](#F2){ref-type="fig"}); again, this readout is markedly decreased in *Gli2^tg^/K17^−/−^* mice ([Fig. 2c](#F2){ref-type="fig"}).

At P40, i.e., prior to onset of histological anomalies ([Fig. 2d](#F2){ref-type="fig"}), MPO activity is 5.9±1.9 fold greater in male *Gli2^tg^* mice relative to females, substantiating the gender bias in this model. MPO activity is lower in P40 male *Gli2^tg^/K17^−/−^* mice (0.55 ± 0.20 relative to female *Gli2^tg^* mice; [Fig. 2e](#F2){ref-type="fig"}). While epidermal thickness is the same ([Fig. 2d](#F2){ref-type="fig"}), mitotic activity is higher in *Gli2^tg^* vs. *Gli2^tg^/K17^−/−^* epidermis at P40 (0.52 ± 0.01 vs. 0.14 ± 0.02 BrdU labeled cells/mm of epidermis) ([Fig. 2f](#F2){ref-type="fig"}) and skin tissue is infiltrated with various types of leukocytes. Barrier integrity is mildy compromised in P40 *Gli2^tg^* ear skin, is again better preserved in *Gli2^tg^/K17^−/−^* mice ([Supplemental Fig. 4a](#SD1){ref-type="supplementary-material"}). Thus, the marked reductions in inflammation and hyperplasia that define *Gli2^tg^/K17^−/−^* ear skin occur as early as P40, ahead of progression to overt tumorigenesis in the *Gli2^tg^* model.

Expression of inflammatory cytokines and chemokines was examined via qRT-PCR in ear tissue at P40 and P80. The findings are stratified according to specific classes of T-helper cytokines: Th1 (cellular immunity; generally "pro-inflammatory"), Th2 (humoral immunity; "anti-inflammatory"), and Th17 (anti-microbial immunity at epithelial barriers)[@R17],[@R18]. Th1 and Th17 hyperactivity occur in psoriasis[@R19]. Absence of K17 in *Gli2^tg^* skin correlates with a marked reduction in Th1- and Th17-related markers and induction of Th2-related markers ([Table 1](#T1){ref-type="table"}), many of which are prominently expressed by skin keratinocytes themselves. Expression of IL-1β, a keratinocyte mitogen[@R20], is \~10 fold higher in *Gli2^tg^* compared to *Gli2^tg^/K17^−/−^* skin ([Table 1](#T1){ref-type="table"}). Immunostaining shows that IL-1β epitopes are strongly expressed in the skin epithelium ([Fig. 2g](#F2){ref-type="fig"}). Spp1 (osteopontin), which acts to bias immune responses toward Th1[@R21], is reduced by \~15 fold and IL-6, associated with the acute phase response and upregulated in human BCC[@R22], is lowered \~17 fold in *Gli2^tg^/K17^−/−^* skin ([Table1](#T1){ref-type="table"}). The matrix metalloproteases MMP3, MMP9 and MMP13, whose expression is enhanced in BCC[@R23], are downregulated in *Gli2^tg^/K17^−/−^* ear tissue. Classical Th2 type cytokines primarily secreted by T-cells, e.g., IL-4 and IL-10, are modestly altered whereas Ccl24 and Ccr4, expressed by skin keratinocytes[@R24], are respectively \~9 and \~3 fold higher in *Gli2^tg^/K17^−/−^* ear tissue ([Table 1](#T1){ref-type="table"}). The expression of many of these cytokines and chemokines is already altered by P40. IL1β and Cxcl5 expression is enhanced in the presence of K17, while the Th2 markers IL20 and IL4 are enhanced in its absence ([Table 1](#T1){ref-type="table"}). Thus, the immunomodulatory influence of K17 is first manifested at an early stage in this model.

Topical application of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA)[@R25], to ear skin induces acute inflammation and epidermal proliferation ([Fig. 3a,b](#F3){ref-type="fig"}), providing a tumor-free, dermatitis-like setting in which to assess the impact of *K17* loss. The latter curtails hyperplasia-driven epidermal thickening (*wt* ear tissue: 34.1±2.3 µm in TPA- vs. 10.4±0.3 µm in vehicle-treated; *K17^−/−^* ear tissue: 18.7± 0.8 µm in TPA- vs. 10.6±0.8 µm in vehicle-treated; [Fig. 3a,b](#F3){ref-type="fig"}). Markers related to compromised skin barrier function (S100A8[@R26], thymic stromal lymphoprotein (TSLP)[@R14], β-defensin [@R27]) show elevated mRNA levels in TPA-treated wildtype skin ([Fig. 3c](#F3){ref-type="fig"}). TSLP and β--defensin are markedly attenuated in *K17^−/−^* skin ([Fig. 3c](#F3){ref-type="fig"}), suggesting better retention of barrier function. A partial shift toward a Th2-dominated cytokine profile is seen in TPA-treated *K17^−/−^* skin, though the magnitude of the changes is less than in *Gli2^tg^* skin. The Th1 chemokines Cxcl5, Ccl3 and IL-1β are reduced 2.4-, 3.0- and 1.7-fold, respectively, and the Th2 cytokine IL-20 is 7.1 fold higher in TPA-treated *K17^−/−^* skin relative to control ([Table 2](#T2){ref-type="table"}). Thus, the *K17* status exerts a similar immunomodulatory influence in acute dermatitis.

Skin keratinocytes from *Gli2^tg^* and *Gli2^tg^/K17^−/−^* newborn mice were seeded for primary culture (48h), and treated with TPA (12h) to assess whether key changes in cytokine/chemokine expression are keratinocyte-autonomous. Under basal conditions, *Gli2^tg^* and *Gli2^tg^/K17^−/−^* cells show rates of proliferation similar to *wt* and *K17^−/−^* ones. TPA induces a two-fold enhancement in *Gli2^tg^* keratinocyte proliferation by 12h, whereas *Gli2^tg^/K17^−/−^* cells are unchanged ([Supplemental Fig. 4b,c](#SD1){ref-type="supplementary-material"}). Again, key chemokines are differentially expressed depending on *K17* status. Levels of Cxcl11, Cxcl5, CxCl9 and Cxcl10 mRNAs, among others, are significantly lower in TPA-treated *Gli2^tg^/K17^−/−^* keratinocytes ([Fig. 3d](#F3){ref-type="fig"} and [Supplemental Fig. 4d](#SD1){ref-type="supplementary-material"}). These chemokines promote keratinocyte proliferation in skin tumors, and show a tight spatial correlation with K17 expression[@R28],[@R29]. Re-expression of K17 into TPA-treated *Gli2^tg^/K17^−/−^* keratinocytes markedly elevates the levels of Cxcl5, CxCl9, and CxCl11 mRNAs, relative to mock-transfected cells ([Fig. 3d](#F3){ref-type="fig"}; [Supplemental Fig. 4d](#SD1){ref-type="supplementary-material"}). Thus, K17 impacts the TPA-induced expression of select chemokines relevant to BCC pathogenesis in both adult epidermis in situ and isolated newborn keratinocytes in culture, suggesting that the mechanism(s) involved are in part cell-autonomous.

Several NF-kB target genes show a modest but consistent reduction in their expression in *Gli2^tg^/K17^−/−^* relative to *Gli2^tg^* keratinocytes in TPA-treated cultures ([Supplemental Figure 5a](#SD1){ref-type="supplementary-material"}). This is consistent with the prominent role of NF-κB in skin inflammatory conditions [@R30] and, in particular, with its impact on Cxcl5, CxCl9, and CxCl11 expression[@R31]--[@R33]. Similar analyses of P80 whole ear skin tissue revealed no difference between the genotypes, likely reflecting the large complexity of these lesions in situ and the occurrence of secondary or compensatory changes ([Supplemental Figure 5, b--c](#SD1){ref-type="supplementary-material"}). Besides, K17 has been shown to promote anagen growth during hair follicle cycling[@R34] and stimulates protein synthesis during tissue repair[@R35]. The phenotype reported here cannot be correlated to obvious alterations in these roles, again as inferred from analyses of skin tissue sections (data not shown) or extracts ([Supplemental Fig. 5, b--d](#SD1){ref-type="supplementary-material"}).

K17 is ectopically expressed in numerous settings associated with robust inflammation including cutaneous wounds, various carcinomas, psoriasis, and virus-induced warts[@R10]. High levels of K17 expression correlate with a poor prognosis in breast[@R36] and pancreatic[@R37] cancers -- whether this phenomenon is related to altered inflammatory signatures represents an issue of interest. There exists a correlation between Th1 hyperactivity and K17 expression in psoriatic plaques[@R19]; plaque resolution coincides with a shift to a Th2 response and loss of K17 expression. We posit that the presence of K17 in epidermis (and related epithelia) promotes hyperplasia in BCC-like tumors (this study) and likely in additional tumors and inflammatory disease settings in part through its ability to promote a specific type of inflammatory response. Normal contexts in which prominent K17 expression is not correlated to local inflammation (e.g., hair follicles) may benefit from an immune-privileged status[@R38] or reflect its regulation via post-translational modifications or interaction with other proteins[@R34],[@R35]. A role for K17 as an immunomodulator, whether direct or indirect, provides a novel way of conceiving how SNPs affecting *K5* influence the risk of developing BCC [@R2], and makes these keratins potentially attractive target for novel therapies aimed at curtailing conditions driven by or linked to chronic inflammation.
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![Absence of K17 delays the onset of ear lesions, and epidermal hyperplasia, in *Gli2^tg^* mice. (a) Age-matched P80 *Gli2^tg^* and *Gli2^tg^/K17^−/−^* male mice. Left, pictures of intact ear. Box highlights lesional tissue in *Gli2^tg^* mice. Arrows point to blood vessels, prominent in *Gli2^tg^* mice. Right, hematoxylin-eosin stained ear tissue section, showing expansion of epidermis (epi). (b), Mean age (± s.e.m.) of onset of macroscopic ear lesions in *Gli2^tg^* and *Gli2^tg^/K17^−/−^* mice, stratified by gender. (c) Percentage of mice with ear lesions at P80 in the *Gli2^tg^*, *Gli2^tg^/K17^−/−^*, and *Gli2^tg^/K14^−/−^* strains of mice. (d) RT-PCR assay of levels of Gli2 transgene expression in *Gli2^tg^* and *Gli2^tg^/K17^−/−^* mice (GAPDH: loading control). (e) Immunostaining for BrdU in ear tissue of P80 male *Gli2^tg^* and *Gli2^tg^/K17^−/−^* mice.epi, epidermis; derm, dermis. (f) Quantitation of BrdU-positive keratinocytes/mm of epidermis seen in (e). (g, h) Immunostaining for phospho-Histone H3 (g), marking mitotic activity, and TUNEL staining (h), detecting apoptotic cells, in P80 male *Gli2^tg^* and *Gli2^tg^/K17^−/−^*. Scale bars: a (50µm), e,g,h (20µm).](nihms231459f1){#F1}

![Role of inflammation in the onset of ear lesions. (a) Immunodetection of infiltrating immune cells and vasculature in *Gli2^tg^* and *Gli2^tg^/K17^−/−^* male mice at P80 using antibodies to CD11b, Thy-1, iNOS, and PECAM-1 (see arrows). Labeling key provided in lower left corner. (b) Quantification of myeloperoxidase activity (MPO; mean ± s.e.m.) in ear tissue of mice at P80, normalized to female *Gli2^tg^* mice. (c) In situ beta-galactosidase staining in P80 male ear tissue of various genotypes. Blue staining reflects loss of barrier integrity. (d) Hematoxylin-eosin stained ear tissue of male mice at P40. (e) Myeloperoxidase activity in ear tissue of P40 male mice, normalized to female *Gli2^tg^* (mean ± s.e.m.). (f) Quantification of BrdU labeled cells/um of epidermis in P40 male mice. (g) Immunostaining for IL-1β in the epidermis (epi) of P80 male ear tissue. Scale bars: a (20µm), c (25µm), d (50µm).](nihms231459f2){#F2}

![Absence of K17 blunts epidermal hyperplasia and alters inflammation in a chemical model of dermatitis. *Wildtype* and *K17^−/−^* mouse ears were treated with acetone (vehicle control) or TPA. (a) Hematoxylin-eosin stained tissue sections depicting the effect of TPA treatment on thickness of epidermis. Right panel: Expansion of basal layer visualized by immunostaining for K14. Scale bars: 20 µm. (b) Epidermal thickness (mean ± s.e.m.), as conveyed by K14 staining, in vehicle (−) and TPA-treated (+) male mouse ears. (c) Right: Semi-quantitative RT-PCR survey of targets associated with loss of barrier integrity. Left: Quantitation of RT-PCR results shown in c. (d) Cytokine/chemokine expression in primary cultures of *Gli2^tg^* and *Gli2^tg^/K17^−/−^* keratinocytes 12 hours after TPA. For d and e, fold change represents changes due to loss of K17 (compilation of 3 assays involving distinct pools of mRNAs). (f) Changes in cytokine and chemokine expression in *Gli2^tg^/K17^−/−^* after reintroduction of K17 via transfection (triplicate).](nihms231459f3){#F3}

###### 

Comparing the inflammatory and immune response in ear lesions, in male *Gli2^tg^/K17^−/−^* relative to male *Gli2^tg^* mice, at P80 and P40. The fold change reported represents alterations in mRNA levels due to loss of *K17*. Values reflect compiled data from three experiments involving distinct pools of cDNAs.

  [Postnatal day 80]{.ul}                           
  ------------------------------- ----------------- -------------
  **Cytokine/Chemokine (Th1)**    **Fold Change**   **P-Value**
                                                    
  Spp1                            −14.83            0.013
  Ccl3                            −14.80            0.003
  Cxcl5                           −10.56            0.007
  IL1β                            −10.20            0.009
  Ccl4                            −8.78             0.016
  Ccr1                            −4.92             0.014
  Cxcr2                           −3.53             0.051
  Ccr5                            −2.53             0.054
  Cxcl10                          −1.73             0.036
  Ccl5                            −1.69             0.022
  TNFα                            −1.18             0.076
  IFNγ                            1.31              0.440
  **Cytokine/Chemokine (Th2)**    **Fold Change**   **P-Value**
                                                    
  Ccl24                           8.85              0.008
  Ccl17                           4.21              0.000
  Ccr4                            3.24              0.004
  Ccl22                           3.09              0.007
  Ccl1                            2.97              0.003
  Ccl11                           2.17              0.046
  IL13                            2.11              0,004
  IL15                            1.62              0.059
  IL4                             1.20              0.100
  IL20                            −1.06             0.900
  **Cytokine/Chemokine (Th17)**   **Fold Change**   **P-Value**
                                                    
  Mmp13                           −25.06            0.001
  Csf3                            −19.57            0.003
  IL6                             −17.12            0.001
  Cxcl2                           −9.99             0.017
  Cxcl5                           −9.37             0.001
  Cxcl1                           −6.52             0.002
  Syk                             −6.46             0.043
  Mmp9                            −5.62             0.004
  Clec7a                          −4.66             0.005
  Mmp3                            −2.67             0.023
  IL10                            −2.46             0.005
  Cd3g                            4.51              0.069
  IL25                            4.01              0.048
  Cd3d                            3.56              0.021
  IL5                             2.51              0.012
  IL15                            1.63              0.035
  [**Postnatal day 40**]{.ul}                       
  **Cytokine/Chemokine (Th1)**    **Fold Change**   **P-Value**
                                                    
  IL1β                            −4.21             0.028
  Cxcl5                           −3.52             0.005
  Ccr1                            −2.96             0.001
  Cxcr2                           −1.98             0.019
  Ccl3                            −1.51             0.233
  **Cytokine/Chemokine (Th2)**    **Fold Change**   **0.014**
                                                    
  IL20                            12.66             0.090
  IL4                             5.24              0.121
  IL13                            5.03              0.110
  Ccl24                           1.59              0.258
  Ccl17                           1.11              0.076

###### 

Comparing the inflammatory and immune response in TPA-treated ear tissue from *K17^−/−^* and wildtype mice. The fold change reported represents alterations in mRNA levels due to loss of *K17*. Values reflect compiled data from three experiments involving distinct pools of cDNAs.

  ------------------------------ ----------------- -------------
  **Cytokine/Chemokine (Th1)**   **Fold Change**   **P-Value**
                                                   
  Ccl3                           −2.97             0.001
  Cxcl5                          −2.44             0.002
  Cxcl1                          −1.90             0.244
  Ccl4                           −1.86             0.009
  IL1β                           −1.70             0.010
  Cxcl9                          −1.20             0.070
  IFNγ                           1.48              0.355
  **Cytokine/Chemokine (Th2)**   **Fold Change**   **P-Value**
                                                   
  IL20                           7.10              0.003
  Ccl22                          1.88              0.004
  IL15                           1.40              0.001
  IL4                            1.20              0.100
  IL10                           1.11              0.356
  ------------------------------ ----------------- -------------
